Comparison of DNA content in primary and lymph node metastases in prostate adenocarcinoma.
There is increasing evidence that nuclear DNA content has significant prognostic value for adenocarcinoma of the prostate. There also appear to be considerable differences in cellular DNA content between patient cohorts when primary tumor or pelvic lymph node metastases are measured. In addition, prostate adenocarcinoma is heterogeneous in DNA measurements; that adds confusion to studies incorporating fine needle aspiration biopsy samples. We compared cellular DNA content in 34 patients with available needle biopsies and pelvic lymph node metastases. Four groups of patients were identified: diploid-range primaries and metastases (8 patients), diploid-range primaries and aneuploid metastases (13), aneuploid primaries and metastases (10), and aneuploid primaries and diploid-range metastases (2). Patients with diploid-range primary tumors had a longer interval to progression and death than did patients with aneuploid primary tumors, although neither was significant in this small series. Patients with diploid-range lymph node metastasis had a longer interval to progression (P = .04) and survival (P = .09) than did individuals with aneuploid metastases. We conclude that the cellular DNA content of prostate cancer metastases in this series of stage D1 patients was more powerful in predicting time to progression and ultimate survival than evaluation of needle biopsy specimens of the primary cancer.
Babiarz
J
J
Department of Urology, Henry Ford Hospital, Detroit, Michigan.
Peters
J M
JM
Miles
B
B
Crissman
J D
JD
D000230:Adenocarcinoma / Q000737:chemistry* / Q000235:genetics / Q000556:secondary; D000368:Aged; D000782:Aneuploidy; D004273:DNA, Neoplasm / Q000032:analysis* / Q000235:genetics; D004171:Diploidy; D006801:Humans; D008207:Lymphatic Metastasis / Q000235:genetics; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000628:therapy
D004273:DNA, Neoplasm